TARSUS PHARMACEUTICALS, INC. Interest Expense
TARSUS PHARMACEUTICALS, INC. (TARS) reported Interest Expense of $983.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-08
- TARSUS PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-03-31 was $983.00K, a 43.71% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-12-31 was $989.00K, a 42.92% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-09-30 was $858.00K, a 35.55% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-06-30 was $815.00K, a 49.82% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest expense for fiscal 2023 was $3.35M, a 52.16% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $2.20M.
- TARSUS PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $983.00K 10-Q · filed 2024-05-08 | $1.97M derived: sum of 2 quarters · filed 2024-05-08 | $2.83M derived: sum of 3 quarters · filed 2024-05-08 | $3.65M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | $989.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.85M derived: sum of 2 quarters · filed 2024-02-27 | $2.66M derived: sum of 3 quarters · filed 2024-02-27 | $3.35M 10-K · filed 2024-02-27 |
| 2023-09-30 | $858.00K 10-Q · filed 2023-11-09 | $1.67M derived: sum of 2 quarters · filed 2023-11-09 | $2.36M 10-Q · filed 2023-11-09 | $3.05M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-06-30 | $815.00K 10-Q · filed 2023-08-10 | $1.50M 10-Q · filed 2023-08-10 | $2.19M derived: sum of 3 quarters · filed 2024-05-08 | $2.82M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-03-31 | $684.00K 10-Q · filed 2024-05-08 | $1.38M derived: sum of 2 quarters · filed 2024-05-08 | $2.01M derived: sum of 3 quarters · filed 2024-05-08 | $2.55M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $692.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.32M derived: sum of 2 quarters · filed 2024-02-27 | $1.87M derived: sum of 3 quarters · filed 2024-02-27 | $2.20M 10-K · filed 2024-02-27 |
| 2022-09-30 | $633.00K 10-Q · filed 2023-11-09 | $1.18M derived: sum of 2 quarters · filed 2023-11-09 | $1.51M 10-Q · filed 2023-11-09 | $1.49M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $544.00K 10-Q · filed 2023-08-10 | $874.00K 10-Q · filed 2023-08-10 | $860.00K derived: sum of 3 quarters · filed 2023-08-10 | $860.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $316.00K 10-Q · filed 2023-05-09 | $316.00K derived: sum of 2 quarters · filed 2023-05-09 | $316.00K derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 derived: sum of 2 quarters · filed 2023-03-17 | $0.00 10-K · filed 2023-03-17 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |